Neuronasal is working to solve two critical medical
needs
disease modifying drug treatment for
October 2024
STTR NIH/NIA grant award to Neuronasal to conduct Phase 1 clinical dose finding research.
NN has developed a novel nose to brain route for n-acetylcysteine (NAC) which is patent protected and has been shown to deliver drug to the targeted brain regions in a human pilot trial.
NAC is an approved drug, which has shown efficacy in human trials with high IV dosing or mega oral doses in the case of Parkinson’s and MTBI respectively. These delivery approaches are not acceptable for patient use.
Neuronasal’s unique Intranasal (IN) delivery method of an FDA approved drug is novel, PATENT PROTECTED as is the method of measuring the level of drug brain delivery.